Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.

Abstract: New glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. Also, pharmaceutical compositions including compounds of Formula (I) for use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels.

Abstract: A method for determining the risk of developing a blood disorder, which includes the steps of: exposing a biological sample from an individual to radiation to obtain a spectrum characteristic of the sample, the spectrum being processed in order to obtain a spectral signature; comparing the spectral signature obtained with one or more reference spectral signatures; and concluding, if the spectral signature of the individual is significantly different from control spectral signatures, that the individual is likely to develop a blood disorder, and, if not, that the individual is not likely to develop a blood disorder.

Abstract: New human therapeutic monoclonal antibodies, which are directed against neutrophil proteinase 3. The monoclonal antibodies are specifically directed against a conformational epitope of the neutrophil proteinase 3 and are capable of inhibiting by at least 30% the production for reactive oxygen derivatives by neutrophils. Also, a pharmaceutical composition including as an active substance at least the monoclonal antibody, and a method for early treatment and/or prevention of relapse of granulomatosis with polyangiitis, which includes the administration of the pharmaceutical composition.

Abstract: A new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.

Abstract: An apparatus and a method for contrast-enhanced ultrasound (CEUS) including use of a fluid dynamics model for the analysis of dynamic contrast-enhanced ultrasound (DCEUS).

Abstract: A strain of an Apicomplexa of the family Sarcocystidae, wherein the strain is replicative and expresses one or more heterologous protein(s) selected from the group including therapeutic proteins, antigens, recombinant surface receptor or combinations thereof, and wherein the strain is selected from the group including Toxoplasma gondii and Neospora caninium. Also, the use of the strain for preventing or treating cancers or infectious diseases in a subject in need thereof.

Abstract: The invention relates to an in vitro method for evaluating digestive efficiency (DE) of poultry, in particular chickens, by measuring color of a sample of liquid fraction of blood of said poultry.

Abstract: This invention relates to an in vitro method for prognosis of the response to a chemotherapy of an individual suffering from chronic myeloid leukemia, comprising a. a step of measuring the expression level of at least one subgroup of genes chosen from a group of genes, b. a comparing step, and c. a step of determining a score S such that—if S is less than 1, said individual will have more than a 40% chance of responding to the chemotherapy, and—if S is greater than or equal to 1, said individual will have less than a 40% chance of responding to the chemotherapy.

Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.

Abstract: The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.

Abstract: A nasal fluid-spray device having: a reservoir containing at least one dose (D) of fluid; and a dispenser system that, each time the device is actuated, sprays a dose (D) of fluid through a spray orifice, generating a spray that extends axially from the spray orifice. The device further includes a generator system for generating a secondary flow, which generator system is actuated simultaneously with the dispenser system, the secondary flow generator system having a secondary flow channel provided with an outlet orifice, the outlet orifice arranged downstream from the spray orifice, and the secondary flow extending from the outlet orifice along an axis (B) that forms an angle (?) relative to the axis (A) of the spray and that intersects the axis (A), thereby deforming and/or deflecting the spray.

Abstract: The present invention relates to a strain of Neospora caninum for use in treating cancer or infectious diseases.

Abstract: An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.

Abstract: The present invention relates to a strain of Neospora caninum for use in treating cancer or infectious diseases.

Abstract: The present invention concerns a method for preparing a composite material comprising electrically conductive or semiconductive nano-objects of elongate shape and an electrically conductive polymer matrix, said method comprising a step consisting in electrochemically deposing said matrix on said nano-objects using a pulsed galvanostatic technique. The present invention also concerns the composite material thus obtained and uses thereof.

Abstract: A process for fabricating a micromechanical structure made of silicon carbide including a cavity, from a stack including a first silicon-carbide layer and a silicon layer on the first silicon-carbide layer, the process including shaping the silicon layer so as to form a discrete silicon structure on the first silicon-carbide layer. The process further includes, after the shaping of the silicon layer, a carbonization to initiate the removal of the discrete silicon structure; depositing a second silicon-carbide layer; and an annealing step, the discrete silicon structure being entirely removed at the end of the annealing.

Abstract: An electrolytic composition including at least one lithium salt of formula (A) wherein Rf represents a fluorine atom, a nitrile group, an optionally fluorinated or perfluorinated alkyl group having from 1 to 5 carbons, an optionally fluorinated or perfluorinated alkoxy group having from 1 to 5 carbons or an optionally fluorinated or perfluorinated oxa-alkoxy group having from 1 to 5 carbons; and the following solvent mixture: ethylene carbonate, ?-butyrolactone, and methyl propanoate. Also, to the use of the compositions in Li-ion batteries.

Abstract: A process for the synthesis of ?-conjugated materials including a step of utilizing a synthon having a carbazole or fluorene nucleus.

Abstract: A pharmaceutical composition for its use in the prophylactic treatment of a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid, without said cationic-polysaccharide core being surrounded by any phospholipidic layer, and at least an antigen obtained from said pathogen.